BioGaia ABBGLAF 100 Altman Z-Score is 26.08 as of Jun. 28, 2026, which is 8% below its 10-year median of 28.28. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 952 Drug Manufacturers companies, BioGaia AB ranks better than 97.37% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 27.18 is strong.
BioGaia AB has a Altman Z-Score of 26.08, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for BioGaia AB's Altman Z-Score or its related term are showing as below:
BGLAF'
s Altman Z-Score Range Over the Past 10 Years
Min: 16.81 Med: 28.28 Max: 47.98
Current: 27.18
During the past 13 years, BioGaia AB's highest Altman Z-Score was 47.98. The lowest was 16.81. And the median was 28.28.
BioGaia AB (OTCPK:BGLAF) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
BioGaia AB Altman Z-Score Related Terms
BioGaia AB Altman Z-Score Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
BioGaia AB's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.6192
+
1.4
*
0
+
3.3
*
0.2515
+
0.6
*
39.3357
+
1.0
*
0.9051
=
26.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
BioGaia AB (BGLAF) has a Altman Z-Score of 26.08 as of Jun. 28, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on BioGaia AB and its competitors. This is near median its historical median of 28.28. Over the past decade, BioGaia AB's Altman Z-Score has ranged from 16.81 to 47.98. According to the industry distribution chart, BioGaia AB ranks #25 out of 952 companies in the Drug Manufacturers industry, placing it in the top 2.6%.
Is BioGaia AB's Altman Z-Score too high?
BioGaia AB's current Altman Z-Score of 26.08 is near median its 10-year median of 28.28. Over the past 10 years, this metric has ranged from a low of 16.81 to a high of 47.98. The Drug Manufacturers industry median Altman Z-Score is 3.30. BioGaia AB's value of 26.08 is 691.5% above this industry median. Based on the distribution chart, BioGaia AB ranks #25 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Altman Z-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #25 out of 952 companies for Altman Z-Score. This places BioGaia AB in the top 3% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.30. BioGaia AB's value of 26.08 is 691.5% above this benchmark. Historically, BioGaia AB's own Altman Z-Score has ranged from 16.81 to 47.98 over the past decade. While the company's 10-year median is 28.28 vs. the industry median of 3.30, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Altman Z-Score of 26.08 is 691.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Altman Z-Score is 26.08, which is near median its own 10-year median of 28.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current Altman Z-Score of 26.08. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Altman Z-Score is 26.08, which is near median its 10-year median of 28.28 and 691.5% above the Drug Manufacturers industry median of 3.30. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Altman Z-Score is 26.08 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
Altman Z-Score: 26.08 (near median its 10-year median of 28.28)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 691.5% above the Drug Manufacturers median (#25 of 952)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
